Please use this identifier to cite or link to this item:
Title: Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature
Author: García García de Paredes, Ana
Manicardi, Nicolo
Tellez, Luis
Ibañez, Luis
Royo, Félix
Bermejo, Javier
Blanco, Carolina
Fondevila Campo, Constantino
Fernández Lanza, Val
García Bermejo, Laura
Falcón Pérez, Juan Manuel
Bañares, Rafael
Gracia Sancho, Jordi
Albillos, Agustín
Keywords: Cirrosi hepàtica
Micro RNAs
Marcadors bioquímics
Hepatic cirrhosis
Biochemical markers
Issue Date: 2-Dec-2020
Publisher: John Wiley & Sons
Abstract: Noninvasive staging of decompensated cirrhosis is an unmet clinical need. The aims of this study were to characterize and validate a novel microRNA (miRNA) signature to stage decompensated cirrhosis and predict the portal pressure and systolic cardiac response to nonselective beta-blockers (NSBBs). Serum samples from patients with decompensated cirrhosis (n = 36) and healthy controls (n = 36) were tested for a novel signature of five miRNAs (miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p) identified in the secretome of primary human hepatocytes and for three miRNAs (miR-192-5p, miR-34a-5p, and miR-29a-5p) previously discovered as biomarkers of chronic liver disease. All patients had ascites, which was refractory in 18 (50%), and were placed on NSBBs for variceal bleeding prophylaxis. In all patients, serum miRNAs, hepatic venous pressure gradient, and an echocardiogram study were performed before and 1 month after NSBBs. Patients with cirrhosis had lower serum levels of miR-429, miR-885-5p, miR-181b-5p, miR-122-5p, miR-192-5p, and miR-29a-5p (P < 0.05). Baseline serum miR-452-5p and miR-429 levels were lower in NSBB responders (P = 0.006). miR-181b-5p levels were greater in refractory ascites than in diuretic-sensitive ascites (P = 0.008) and correlated with serum creatinine. miR-452-5p and miR-885-5p were inversely correlated with baseline systemic vascular resistance (ρ = −0.46, P = 0.007; and ρ = −0.41, P = 0.01, respectively) and with diminished systolic contractility (ρ = −0.55, P = 0.02; and ρ = −0.55, P = 0.02, respectively) in patients with refractory ascites after NSBBs. Conclusion: Analysis of a miRNA signature in serum discriminates between patients with decompensated cirrhosis who show more severe systemic circulatory dysfunction and compromised systolic function after beta-blockade and those more likely to benefit from NSBBs.
Note: Reproducció del document publicat a:
It is part of: Hepatology Communications, 2020, vol. 5, num. 2, p. 309-322
Related resource:
ISSN: 2471-254X
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
705487.pdf969.85 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons